Skip to main content

Bruker Cites Quarterly Fluctuations for Flat Q3 Revenues

NEW YORK (GenomeWeb News) – Bruker today reported nearly flat third-quarter revenue growth and a decrease in profits, due to higher spending and expected quarterly fluctuations in purchases by customers.
 
The Billerica, Mass.-based firm brought in revenues of $242.1 million for the three-month period ended Sept. 30, nearly flat with revenues of $241.8 million in the third quarter of 2007. Excluding currency benefits, Bruker's revenues fell 7 percent year over year.
 
“Since our February 2008 merger [with affiliated firm Bruker BioSpin] we have experienced significant quarterly fluctuations,” Bruker President and CEO Frank Laukien said in a statement. “As in previous years, we expect strong revenues in our fourth quarter of 2008, as our bookings and backlog have remained healthy.”
 
Bruker's third-quarter profits declined 33 percent to $17.8 million, or $.11 per share, from $26.7 million, or $.16 per share.
 
The firm's SG&A spending increased around 15 percent to $61.8 million from $53.9 million, while its R&D expenses rose 23 percent $33.1 million from $26.8 million.
 
Laukien noted that beginning this past summer the firm began taking steps to reduce its operating and interest expense and reduce its exposure to currency fluctuations. “We expect that our cost-cutting initiatives will already have noticeable positive effects in the fourth quarter of 2008 and first quarter of 2009, and that by the middle of 2009 we will see annualized reductions in our overall costs of greater than $12 million,” said Laukien.
 
Bruker finished the quarter with $87.4 million in cash and short-term investments.
 
The company's shares dropped nearly 30 percent during the day, to close at $3.66.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.